Phase II study of continuous intravenous infusion of recombinant interleukin-2 in patients with advanced renal cell carcinoma

M. Lopez, S. Carpano, A. Cancrini, M. Marcellini, P. Del Medico, M. Rinaldi, P. Vici, G. Paoletti, L. Di Lauro

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The goal of this study was to evaluate the therapeutic efficacy and toxicity of recombinant interleukin-2 (rIL-2) administered by continuous intravenous (CIV) infusion to patients with metastatic renal cell cancer (RCC).Patients and methods: Thirty patients with RCC were given rIL-2 18 MIU/m2/d CIV. The schedule consisted of two induction cycles and four maintenance cycles with a 3-week rest period between cycles. Each induction cycle consisted of two infusion periods lasting 120 and 108 hours, respectively, separated by a 6-day rest period. Each maintenance cycle consisted of a 120-hour infusion period.Results: Among 29 assessable patients, the objective response rate was 14% (95% confidence interval, 2% to 26%); one patient achieved a complete response, and 3 partial responses. Ten patients (34%) had stable disease (SD). Median survival was 11 months. Toxicity was generally manageable. Hypotension was universal, but required dose reduction in only 2 patients. Increase in serum creatinine levels was observed in 20 patients, and returned to normal in all but 4 patients after discontinuation of treatment.Conclusion: Results confirm the efficacy of rIL-2 in patients with RCC and the feasibility of the treatment in a normal oncology ward. However, responses are observed in a minority of patients, and treatment-related toxicity, as well as technical problems, may be troublesome to many patients.

Original languageEnglish
Pages (from-to)689-691
Number of pages3
JournalAnnals of Oncology
Volume4
Issue number8
Publication statusPublished - Sep 1993

Keywords

  • Continuous intravenous infusion
  • Interleukin-2
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II study of continuous intravenous infusion of recombinant interleukin-2 in patients with advanced renal cell carcinoma'. Together they form a unique fingerprint.

Cite this